Simon Alan E, Akinbami Lara J
Infant, Child, and Women's Health Statistics Branch, Office of Analysis and Epidemiology, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD, USA.
J Asthma. 2013 May;50(4):419-26. doi: 10.3109/02770903.2013.769269. Epub 2013 Feb 27.
National Asthma Education and Prevention Program recommended emergency department (ED) asthma treatment includes both providing systemic corticosteroids in the ED and a steroid prescription at discharge.
To examine the prevalence of three types of substandard ED asthma care-providing a discharge prescription only, providing corticosteroids in the ED only, and providing neither- and how care varies with exacerbation severity.
We used the National Hospital Ambulatory Medical Care Survey-Emergency Department (NHAMCS-ED) (2007, 2008, and 2009) to identify ED asthma visits (International Classification of Diseases-9(th) Revision Clinical Modification (ICD-9-CM codes 493.xx)) for patients aged 1 to <65 years. The primary outcome was the percent of visits receiving each type of substandard care, both overall and by exacerbation severity. Multinomial logistic regressions with predictive margins were used to obtain estimates adjusted for patient, visit, and hospital characteristics.
For 27.1% (confidence interval (CI): 24.0-30.2%) of visits, patients received corticosteroids both in the ED and as a discharge prescription. A discharge prescription only was provided for 12.3% of visits (CI: 10.2-14.6%), corticosteroids were provided in the ED only for 18.2% (CI: 15.6-21.2%), and no corticosteroids were provided for 42.4% (CI: 38.8-46.2%). Even among visits by patients with abnormal overall respiratory status (fast respiratory rates, pulse oximetry values <97%, or both), only 32.3% (CI: 27.8-36.8) were provided corticosteroids both in the ED and as a prescription, while the remainder received some type of substandard care. Adjusted and unadjusted results were similar.
Substandard ED asthma care is common, even among visits by patients with more severe asthma exacerbations.
国家哮喘教育与预防计划推荐的急诊科哮喘治疗包括在急诊科给予全身用糖皮质激素以及出院时开具糖皮质激素处方。
研究三种不合格的急诊科哮喘治疗的发生率,即仅开具出院处方、仅在急诊科给予糖皮质激素以及两者均未给予,以及治疗如何随加重严重程度而变化。
我们使用国家医院门诊医疗调查-急诊科(NHAMCS-ED)(2007年、2008年和2009年)来识别1至<65岁患者的急诊科哮喘就诊情况(国际疾病分类第9版临床修订本(ICD-9-CM编码493.xx))。主要结局是接受每种不合格治疗类型的就诊百分比,包括总体情况以及按加重严重程度划分的情况。使用带有预测边际的多项逻辑回归来获得针对患者、就诊和医院特征进行调整后的估计值。
在27.1%(置信区间(CI):24.0 - 30.2%)的就诊中,患者在急诊科和出院时均接受了糖皮质激素治疗。仅12.3%的就诊(CI:10.2 - 14.6%)开具了出院处方,仅18.2%的就诊(CI:15.6 - 21.2%)在急诊科给予了糖皮质激素,42.4%的就诊(CI:38.8 - 46.2%)未给予糖皮质激素。即使在总体呼吸状态异常(呼吸频率快、脉搏血氧饱和度值<97%或两者皆有)的患者就诊中,也只有32.3%(CI:27.8 - 36.8)在急诊科和出院时均接受了糖皮质激素治疗,而其余患者接受了某种类型的不合格治疗。调整后和未调整的结果相似。
不合格的急诊科哮喘治疗很常见,即使在哮喘加重更严重的患者就诊中也是如此。